Diabetes Clinical Trials in Phoenix, AZ

39 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment	N/A	Aventyn, Inc.	<1 mi
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease	Phase 3	Boehringer Ingelheim	<1 mi
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)	Phase 3	Eli Lilly and Company	<1 mi
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes	Phase 2	Eli Lilly and Company	<1 mi
A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting	—	Bayer	<1 mi
A Clinical Investigation Evaluating Wound Closure with OptiPulse™ Versus SOC in the Treatment of Non-Healing DFU's	N/A	Compedica Inc	<1 mi
Efficacy of Placental Membrane Dressings in Accelerating Diabetic Foot Healing	Phase 4	BioXTek	<1 mi
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy	Phase 2	Boehringer Ingelheim	<1 mi
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma	Phase 2	Children's Oncology Group	<1 mi
EDX110 Randomized Control Trial for Treatment of DFUs	N/A	ConvaTec Inc.	<1 mi
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial	N/A	Sonavex, Inc.	<1 mi
Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus	N/A	Well Cell Global	<1 mi
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight	Phase 3	Eli Lilly and Company	<1 mi
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes	Phase 3	Kailera	<1 mi
Family Investigation of Nephropathy and Diabetes (F.I.N.D.)	—	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	<1 mi
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin	Phase 3	Eli Lilly and Company	<1 mi
DISCOVERY of Risk Factors for Type 2 Diabetes in Youth	—	George Washington University	<1 mi
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide	Phase 2	Eli Lilly and Company	<1 mi
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes	Phase 4	VA Office of Research and Development	<1 mi
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis	Phase 2/3	CSL Behring	<1 mi
American Indian Chronic Renal Insufficiency Cohort Study (AI-CRIC Study)	—	University of New Mexico	<1 mi
Smart Walk: A Culturally Tailored Smartphone-Delivered Physical Activity Intervention for African American Women	Phase 2	Arizona State University	<1 mi
Early Tracking of Childhood Health Determinants (ETCHED) Study	—	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	<1 mi
WatchWell: Simple and Practical Strategies to Reduce the Negative Health Impact of Sedentary Screen Time	N/A	Arizona State University	10 mi
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)	Phase 3	Viking Therapeutics, Inc.	11 mi
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events	N/A	Cleerly, Inc.	11 mi
Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project	—	CND Life Sciences	11 mi
Gastroparesis Registry 4	—	Johns Hopkins Bloomberg School of Public Health	11 mi
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes	Phase 3	Eli Lilly and Company	11 mi
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes	Phase 3	Sanofi	11 mi
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes	Phase 3	vTv Therapeutics	11 mi
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)	Phase 1/2	GI Innovation, Inc.	11 mi
Balance4Mobility: Effects of Walkasins Use in Individuals With Peripheral Neuropathy and Balance Problems	N/A	RxFunction Inc.	15 mi
Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers	N/A	Piomic Medical	15 mi
Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes	Phase 3	Kailera	15 mi
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)	Phase 2	Sparrow Pharmaceuticals	17 mi
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes	Phase 3	Eli Lilly and Company	21 mi
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity	Phase 3	Eli Lilly and Company	21 mi
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes	Phase 3	Eli Lilly and Company	21 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.